FDA Lifts Clinical Hold on Antisense Therapeutics Trials

October 5, 2017

The FDA lifted its full clinical hold for Antisense Therapeutics’ clinical study for its multiple sclerosis candidate.

Antisense’s phase IIb clinical study for the candidate may now proceed at a 25mg/week dose for six months under a partial hold, according to the company.

The next step for Antisense will be to seek clarification from the agency on the circumstances under which it may give MS patients higher doses in future trials.

View today's stories